Suppose that we were spending another $50 billion a year on medical research in order to replace patent-supported research, and [...] all drugs were sold as generics. The annual deficit would be $50 billion higher due to the additional spending [...] but we would save $380 billion a year on drugs due to generic pricing. In Washington policy circles, the high-drug-price scenario would be the path of fiscal prudence and caring about our children.